Mov Disord:帕金森患者,外周血的免疫特征如何?

2021-08-08 Freeman MedSci原创

与HCs相比,PD患者的外周免疫谱发生改变,NLR较高。

帕金森病(PD)是最常见的神经退行性疾病之一,但其发病机制仍不清楚。

目前的证据表明,神经炎症是帕金森病神经退行性疾病的病因和进展的一个主要因素。神经炎症不是对神经变性的简单反应,PD与中枢和外周的免疫反应都有关。

有证据表明,在PD中存在着脑-外周的相互作用,或者是通过胶质-淋巴途径,或者是通过血脑屏障的干扰。

据描述,与健康对照组(HCs)相比,PD患者的血液、脑脊液(CSF)和大脑中的促炎症细胞因子升高了。

在PD患者的外周血中,白细胞及其亚群的数量和质量都发生了变化。中性粒细胞与淋巴细胞比率(neutrophil-to-lymphocyte ratio,NLR)是一个公认的机体整体炎症状态的指标。

该比率整合了两种白细胞亚群和互补的免疫途径的信息:中性粒细胞与慢性炎症有关,而淋巴细胞可能代表调节途径。它已被用作癌症、血管和炎症性疾病的预后因素,以及阿尔茨海默病的认知障碍的标志物。有人认为NLR在PD中升高,作为外周炎症的生物标志物,但结果有争议。

藉此,西班牙Universitario Virgen del Rocío的Laura Muñoz-Delgado等人,探究了PD患者与HCs相比,是否存在促炎症的外周免疫状态。

他们首先通过病例对照研究探究了PD患者和HCs之间外周免疫状况的差异。

然后,探究了NLR是否与PD的临床特征有关。

最后,进行了荟萃分析以澄清NLR在PD中的作用。

他们发现:在病例对照研究中,PD患者的NLR明显高于HCs(2.47 ± 1.1 vs. 1.98 ± 0.91,P < 0.001)。

但没有发现NLR与发病年龄、疾病严重程度或疾病持续时间之间的关联。

荟萃分析显示,PD患者的NLR可能更高。

这个研究的重要意义在于发现了:与HCs相比,PD患者的外周免疫谱发生改变,NLR较高。


原文出处:
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson’s Disease. Mov Disord. Published online June 8, 2021:mds.28685. doi:10.1002/mds.28685

 
 
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-10-16 cmsvly
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 ms3000000120045871

    有收获

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 ms812711744394816

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 jyq1990

    0

相关资讯

Mov Disord:血液中的细胞外囊泡,可有效诊断帕金森

德国波恩大学研究团队发现血浆胞外囊泡中的α-synuclein浓度,可作为PD的潜在诊断生物标志物。

Mov Disord-新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

Mov Disord:认知行为疗法,有助于减轻帕金森患者的焦虑状态?

认知行为疗法,有助于减轻帕金森患者的焦虑状态?

Mov Disord:神经黑色素变化,和帕金森病的恶化高度相关

神经黑色素变化,和帕金森病的恶化高度相关

Mov Disord:双侧卵巢切除术后,女性更容易患帕金森病

双侧卵巢切除术后,女性更容易患帕金森病。

Mov Disord:早期帕金森患者,脑脊液的神经递质如何变化?

早期帕金森患者,脑脊液的神经递质如何变化?

拓展阅读

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

好文推荐 | 帕金森病睡眠障碍结构特征及其影响因素的临床研究

探讨帕金森病(PD)患者睡眠障碍的发生率、睡眠结构特征、影响因素。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10